According to the World Health Organization, WHO, the vaccine market has grown from 38 billion doses and $5.8 billion in sales in 2019, before the pandemic, to 141 billion doses and a turnover of 16 billion dollars, following the marketing of two vaccines with ARS messenger, by Pfeizer and Moderna the other vaccines, have been ousted in favor of the first, while the vaccines with ARS messenger do not hold their promises, the world is still waiting for the vaccine that will protect both once morest contamination and once morest its effects for the duration of the epidemic, while we are currently on the fourth injection and the fifth is offered to fragile people.
Protection once morest Covid-19 has changed the conception of the development of vaccines by pharmaceutical companies, by demonstrating that it was possible in a few months, whereas in the past, it took ten years, until the implementation on the market for a vaccine, while making it possible to start marketing with little means, in this case, Pfeizer and Moderna pulled out all the stops to bring out the vaccine that the world was waiting for and that it was ready to pay for the right price.
From this experience there is a lesson to be learned, the sector which needs enormous and very risky investments has concentrated on four heavyweights GSK, Sanofi, MSD and Pfizer, while others have withdrawn like the Swiss Novartis , which sold its vaccines business to GSK.
All announce the release of many vaccines in the years to come, which will make it possible to treat diseases which are not currently covered at the vaccine level, hence an acceleration of R&D, new in the vaccine industry.
